Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily With Emtricitabine and Tenofovir Disoproxil Fumarate for Previously Untreated HIV1 Infection Week 96 Results From ONCEMRK a Randomized DoubleBlind Noninferiority Trial

Simple item page
dc.citation.doi10.1097/QAI.0000000000001723
dc.citation.epage598
dc.citation.spage589
dc.contributor.authorPedro Cahn
dc.contributor.authorPaul E Sax
dc.contributor.authorKathleen Squires
dc.contributor.authorJean-Michel Molina
dc.contributor.authorMohammed Rassool
dc.contributor.authorE et al
dc.date.accessioned2023-04-13T10:33:05Z
dc.date.available2023-04-13T10:33:05Z
dc.identifier.citationISI
dc.identifier.issn1525-4135
dc.identifier.urihttps://hdl.handle.net/10539/35040
dc.journal.titleJAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
dc.journal.volume78
dc.titleRaltegravir 1200 mg Once Daily vs 400 mg Twice Daily With Emtricitabine and Tenofovir Disoproxil Fumarate for Previously Untreated HIV1 Infection Week 96 Results From ONCEMRK a Randomized DoubleBlind Noninferiority Trial
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Journal.pdf
Size:
1.03 MB
Format:
Adobe Portable Document Format
Description:
Journal
Download
Collections
Academic Wits Research Outputs (All submissions)